Accipiter Life Sciences Fund

Accipiter Biosciences is a Seattle-based biotechnology company pioneering the design of de novo multifunctional biologics for complex diseases. Utilizing an advanced computational platform paired with high-throughput experimentation, the company engineers entirely new proteins from scratch that integrate multiple mechanisms of action into a single, stable molecule. This "post-evolutionary biologics" approach aims to replace traditional drug combinations with more precise, single-molecule therapies capable of activating multiple cellular pathways simultaneously. Accipiter has established strategic research collaborations with Pfizer and Kite Pharma to develop novel biologics across various therapeutic targets and is currently advancing its own internal pipeline in immunology and oncology.